People Background Check
Find People:

Jaymin C Shah, Age 671092 The Dalles Ave, Sunnyvale, CA 94087

Get Report
Known as:
Jamin C Shah
Related to:
Tom V Le 73 Kathy T Nguyen 40

Jaymin Shah Phones & Addresses

1092 The Dalles Ave, Sunnyvale, CA 94087 (408) 749-1952

1440 Belleville Way, Sunnyvale, CA 94087 (408) 749-1952

Merced, CA

San Jose, CA

San Diego, CA

Palo Alto, CA

Mountain View, CA

Santa Clara, CA

1092 The Dalles Ave, Sunnyvale, CA 94087 (510) 229-0286

Show more

Work

Position: Service Occupations

Education

Degree: Associate degree or higher

Emails

f***[email protected]

Mentions for Jaymin C Shah

Career records & work history

Medicine Doctors

Jaymin R. Shah

Specialties:
Anesthesiology
Education:
Medical School
Midwestern University/ Chicago College of Osteopathic Medicine
Graduated: 2005
Procedures:
Arthrocentesis, Osteopathic Manipulative Treatment
Conditions:
Ankylosing Spondylitis (AS), Anxiety Phobic Disorders, Diabetes Mellitus (DM), Disorders of Lipoid Metabolism, Fractures, Dislocations, Derangement, and Sprains, Gout, Inflammatory Bowel Disease (IBD), Intervertebral Disc Degeneration, Migraine Headache, Osteoarthritis, Overweight and Obesity, Peripheral Nerve Disorders, Rheumatoid Arthritis, Sciatica, Scoliosis or Kyphoscoliosis, Spinal Stenosis, Tempromandibular Joint Disorders (TMJ)
Description:
Dr. Shah graduated from the Midwestern University/ Chicago College of Osteopathic Medicine in 2005. He works in Janesville, WI and specializes in Anesthesiology. Dr. Shah is affiliated with Mercy Hospital & Trauma Center and Mercy Walworth Hospital & Medical Center.

Jaymin Shah resumes & CV records

Resumes

Jaymin Shah Photo 21

Senior Application Consultant - Java Full Stack

Location:
Sunnyvale, CA
Industry:
Information Technology And Services
Work:
Sirius Xm Radio Inc.
Senior Application Consultant - Java Full Stack Major League Baseball Oct 2016 - Jun 2017
Software Engineer - Java Unitedhealth Group Jan 2016 - Oct 2016
Software Engineer One Advanced May 2012 - Oct 2015
Senior Software Engineer - Java Practice Nihilent Technologies Jun 2010 - May 2012
System Analyst Pocit 2011 - 2011
Java Developer Magic Infocom Pvt. Ltd. Oct 2009 - Jun 2010
Java Developer Aptegra Solutions Private Limited Jun 2007 - Sep 2009
Project Leader and Software Engineer
Education:
Harrisburg University of Science and Technology 2015 - 2017
Master of Science, Masters, Management, Engineering Gujarat University 2003 - 2007
Bachelor of Engineering, Bachelors
Skills:
Java, Javascript, Java Enterprise Edition, Sql, Web Services, Sdlc, Jsp, Requirements Analysis, Html 5, Hibernate, Xml, Ajax, Oracle, Servlets, Ejb, Databases, Mysql, Agile Methodologies, Software Development, Struts, Software Project Management, Tomcat, Eclipse, Spring Framework, Jdbc, Jsf, Json, Css, Spring, Soa, Scrum, Subversion, Design Patterns, Oop, Ant, Mvc, Jquery, Core Java, Web Development, Pl/Sql, Html5, Cascading Style Sheets, Javaserver Pages, Dojo, Dhtmlx, Linux System Administration, Jboss Application Server, Ireport, Drools
Interests:
Children
Environment
Science and Technology
Disaster and Humanitarian Relief
Human Rights
Animal Welfare
Arts and Culture
Health
Languages:
English
Hindi
Gujarati
Jaymin Shah Photo 22

Executive Director, Clinical Pharmacology

Location:
Berkeley, CA
Industry:
Pharmaceuticals
Work:
Gilead Sciences 2002 - 2006
Senior Director, Clinical Pharmacology Durect Corporation 2002 - 2006
Executive Director, Clinical Pharmacology Elan 1999 - 2002
Senior Director, Clinical Pharmacology Alza Corporation 1995 - 1999
Associate Director, Clinical Pharmacology Syntex Research 1988 - 1995
Scientist
Education:
University of Missouri - Kansas City 1983 - 1988
Doctorates, Doctor of Philosophy Virginia Commonwealth University 1981 - 1983
Karnataka Law College, Dharwad 1976 - 1980
Bachelors, Bachelor of Pharmacy, Pharmacy
Skills:
Clinical Pharmacology
Jaymin Shah Photo 23

Jaymin Shah

Jaymin Shah Photo 24

Jaymin Shah

Publications & IP owners

Us Patents

Method For Increasing The Bioavailability Of Metaxalone

US Patent:
6407128, Jun 18, 2002
Filed:
Dec 3, 2001
Appl. No.:
09/998206
Inventors:
Michael Scaife - Poway CA
Jaymin Shah - Sunnyvale CA
Assignee:
Elan Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61K 3142
US Classification:
514376
Abstract:
A method of increasing the bioavailability of metaxalone by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of metaxalone in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.

Methods Of Using Metaxalone In The Treatment Of Musculoskeletal Conditions

US Patent:
6683102, Jan 27, 2004
Filed:
Mar 25, 2002
Appl. No.:
10/104044
Inventors:
Michael Scaife - Poway CA, 92064
Jaymin Shah - Sunnyvale CA, 94086
Assignee:
Elan Pharmaceuticals, Inc. - South San Francisco GA
International Classification:
A61K 3142
US Classification:
514376
Abstract:
A method of increasing the bioavailability of metaxalone by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of metaxalone in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.

Transoral Dosage Forms Comprising Sufentanil And Naloxone

US Patent:
2010001, Jan 14, 2010
Filed:
Feb 8, 2008
Appl. No.:
12/449292
Inventors:
Su Yum, II - Los Altos CA, US
Jaymin Shah - Sunnyvale CA, US
Sung Yun Kwon - Fremont CA, US
Xiaoping Song - San Jose CA, US
International Classification:
A61K 31/4535
A61K 31/485
US Classification:
514282, 514326
Abstract:
The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test. Related dosage forms are also disclosed. Also disclosed are transoral dosage forms and related methods, wherein a transoral dosage form may comprise: (1) about 5 to about 1000 micrograms of sufentanil; (2) about 50 micrograms to about 100 milligrams of naloxone; and (3) acidifying material in an amount sufficient to provide a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test; wherein the dosing period begins no earlier than about 1 minute after administration of the transoral dosage form, and ends no later than about 120 minutes after administration of the transoral dosage form.

Oral Pharmaceutical Dosage Forms

US Patent:
2010026, Oct 14, 2010
Filed:
Nov 3, 2009
Appl. No.:
12/590195
Inventors:
Jan J. Scicinski - Sunnyvale CA, US
William W. van Osdol - Mountain View CA, US
Michael H. Arenberg - Campbell CA, US
Jaymin Shah - Sunnyvale CA, US
International Classification:
A61K 31/445
A61K 9/00
A61P 25/00
US Classification:
424484, 514317
Abstract:
Controlled release oral dosage forms suitable for administration of methylphenidate are provided. Abuse-resistant controlled release oral dosage forms suitable for administration of methylphenidate are also provided. Methods of treating ADD and ADHD using the oral dosage forms are also provided.

Oral Pharmaceutical Dosage Forms

US Patent:
2014001, Jan 9, 2014
Filed:
Jun 21, 2013
Appl. No.:
13/924232
Inventors:
William W. van Osdol - Mountain View CA, US
Michael H. Arenberg - Campbell CA, US
Jaymin Shah - Sunnyvale CA, US
International Classification:
A61K 31/4458
A61K 9/00
US Classification:
514317
Abstract:
Controlled release oral dosage forms suitable for administration of methylphenidate are provided. Abuse-resistant controlled release oral dosage forms suitable for administration of methylphenidate are also provided. Methods of treating ADD and ADHD using the oral dosage forms are also provided.

Transoral Dosage Forms Comprising Sufentanil And Naloxone

US Patent:
2020028, Sep 10, 2020
Filed:
Feb 13, 2020
Appl. No.:
16/790207
Inventors:
- Cupertino CA, US
Jaymin Shah - Sunnyvale CA, US
Sung Yun Kwon - Fremont CA, US
Xiaoping Song - Saratoga CA, US
International Classification:
A61K 31/4535
A61K 9/00
A61K 9/06
A61K 31/485
Abstract:
The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test. Related dosage forms are also disclosed. Also disclosed are transoral dosage forms and related methods, wherein a transoral dosage form may comprise: (1) about 5 to about 1000 micrograms of sufentanil; (2) about 50 micrograms to about 100 milligrams of naloxone; and (3) acidifying material in an amount sufficient to provide a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test; wherein the dosing period begins no earlier than about 1 minute after administration of the transoral dosage form, and ends no later than about 120 minutes after administration of the transoral dosage form.

Oral Pharmaceutical Dosage Forms

US Patent:
2020000, Jan 2, 2020
Filed:
May 7, 2019
Appl. No.:
16/405902
Inventors:
- Cupertino CA, US
William W. van Osdol - Mountain View CA, US
Huey-Ching Su - San Jose CA, US
Michael H. Arenberg - Campbell CA, US
Jaymin Shah - Sunnyvale CA, US
International Classification:
A61K 31/4458
A61K 9/16
A61K 9/48
A61K 9/50
A61K 9/00
Abstract:
Controlled release oral dosage forms suitable for administration of methylphenidate are provided. Abuse-resistant controlled release oral dosage forms suitable for administration of methylphenidate are also provided. Methods of treating ADD and ADHD using the oral dosage forms are also provided.

Transoral Dosage Forms Comprising Sufentanil And Naloxone

US Patent:
2018022, Aug 16, 2018
Filed:
Jan 12, 2018
Appl. No.:
15/870625
Inventors:
- Cupertino CA, US
Jaymin Shah - Sunnyvale CA, US
Sung Yun Kwon - Fremont CA, US
Xiaoping Song - Saratoga CA, US
Assignee:
Durect Corporation - Cupertino CA
International Classification:
A61K 31/4535
A61K 31/485
A61K 9/06
A61K 9/00
A61K 9/70
A61K 9/20
Abstract:
The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test. Related dosage forms are also disclosed. Also disclosed are transoral dosage forms and related methods, wherein a transoral dosage form may comprise: (1) about 5 to about 1000 micrograms of sufentanil; (2) about 50 micrograms to about 100 milligrams of naloxone; and (3) acidifying material in an amount sufficient to provide a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test; wherein the dosing period begins no earlier than about 1 minute after administration of the transoral dosage form, and ends no later than about 120 minutes after administration of the transoral dosage form.

Possible Relatives

David M Shah  Aamir S Shah  Deep J Shah  Deepa Shah  Deepal D Shah  Deepali S Shah  Deepika J Shah 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.